1
|
Singh Y, Bhatia N, Biharee A, Kulkarni S, Thareja S, Monga V. Developing our knowledge of the quinolone scaffold and its value to anticancer drug design. Expert Opin Drug Discov 2023; 18:1151-1167. [PMID: 37592843 DOI: 10.1080/17460441.2023.2246366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2023] [Accepted: 08/07/2023] [Indexed: 08/19/2023]
Abstract
INTRODUCTION The quinolone scaffold is a bicyclic benzene-pyridinic ring scaffold with nitrogen at the first position and a carbonyl group at the second or fourth position. It is endowed with a diverse spectrum of pharmacological activities, including antitumor activity, and has progressed into various development phases of clinical trials for their target-specific anticancer activity. AREAS COVERED The present review covers both classes of quinolones, i.e. quinolin-2(H)-one and quinolin-4(H)-one as anticancer agents, along with their possible mode of binding. Furthermore, their structure-activity relationships, molecular mechanisms, and pharmacokinetic properties are also covered to provide insight into their structural requirements for their rational design as anticancer agents. EXPERT OPINION Synthetic feasibility and ease of derivatization at multiple positions, has allowed medicinal chemists to explore quinolones and their chemical diversity to discover newer anticancer agents. The presence of both hydrogen bond donor (-NH) and acceptor (-C=O) functionality in the basic scaffold at two different positions, has broadened the research scope. In particular, substitution at the -NH functionality of the quinolone motif has provided ample space for suitable functionalization and appropriate substitution at the quinolone's third, sixth, and seventh carbons, resulting in selective anticancer agents binding specifically with various drug targets.
Collapse
Affiliation(s)
- Yogesh Singh
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| | - Neha Bhatia
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| | - Avadh Biharee
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| | - Swanand Kulkarni
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| | - Suresh Thareja
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| | - Vikramdeep Monga
- Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab, Bathinda, India
| |
Collapse
|
2
|
Dine I, Mulugeta E, Melaku Y, Belete M. Recent advances in the synthesis of pharmaceutically active 4-quinolone and its analogues: a review. RSC Adv 2023; 13:8657-8682. [PMID: 36936849 PMCID: PMC10015437 DOI: 10.1039/d3ra00749a] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2023] [Accepted: 03/01/2023] [Indexed: 03/17/2023] Open
Abstract
4-Quinolone and its analogs are heterocyclic classes of organic compounds displaying biologically active and a broad spectrum of pharmaceutical drug scaffolds. 4-Quinolone is the first-line chemotherapeutic treatment for a wide spectrum of bacterial infections. Recently, 4-quinolone and its derivatives have been shown to have the potential to cure and regulate various acute and chronic diseases, including pain, ischemia, immunomodulation, inflammation, malarial, bacterial infection, fungal infection, HIV, and cancer, based on several reports. This review highlights and provides brief information to better understand the development of experimental progress made to date in the synthetic protocol towards 4-quinolone and its analogs. Thus, classical synthesis protocol, metal-free reaction protocol, and transition metal-catalyzed reaction procedures are briefly discussed along with the pharmaceutical activities of selected 4-quinolone derivatives.
Collapse
Affiliation(s)
- Ilili Dine
- Department of Applied Chemistry, School of Applied Natural Science, Adama Science and Technology University P.O. Box 1888 Adama Ethiopia
| | - Endale Mulugeta
- Department of Applied Chemistry, School of Applied Natural Science, Adama Science and Technology University P.O. Box 1888 Adama Ethiopia
| | - Yadessa Melaku
- Department of Applied Chemistry, School of Applied Natural Science, Adama Science and Technology University P.O. Box 1888 Adama Ethiopia
| | - Melis Belete
- Department of Applied Chemistry, School of Applied Natural Science, Adama Science and Technology University P.O. Box 1888 Adama Ethiopia
| |
Collapse
|
3
|
Sharma V, Das R, Kumar Mehta D, Gupta S, Venugopala KN, Mailavaram R, Nair AB, Shakya AK, Kishore Deb P. Recent insight into the biological activities and SAR of quinolone derivatives as multifunctional scaffold. Bioorg Med Chem 2022; 59:116674. [DOI: 10.1016/j.bmc.2022.116674] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 02/07/2022] [Accepted: 02/13/2022] [Indexed: 01/09/2023]
|
4
|
Angeles CV, Velez A, Rios J, Laxa B, Shum D, Ruiz PD, Shen Y, Ostrovnaya I, Gularte-Mérida R, Nacev BA, Dickson MA, Djaballah H, Okada T, Singer S. A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma. Clin Cancer Res 2021; 28:175-186. [PMID: 34667024 DOI: 10.1158/1078-0432.ccr-19-2486] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 06/21/2021] [Accepted: 10/15/2021] [Indexed: 11/16/2022]
Abstract
PURPOSE Dedifferentiated liposarcoma (DDLS), one of the most common and aggressive sarcomas, infrequently responds to chemotherapy. DDLS survival and growth depend on underexpression of C/EBPα, a tumor suppressor and transcriptional regulator controlling adipogenesis. We sought to screen and prioritize candidate drugs that increase C/EBPα expression and may therefore serve as differentiation-based therapies for DDLS. EXPERIMENTAL DESIGN We screened known bioactive compounds for the ability to restore C/EBPα expression and inhibit proliferation selectively in two DDLS cell lines but not in normal adipose-derived stem cells (ASC). Selected hits' activity was validated, and the mechanism of the most potent, SN-38, was investigated. The in vivo efficacy of irinotecan, the prodrug of SN-38, was evaluated in DDLS xenograft models. RESULTS Of 3,119 compounds, screen criteria were met by 19. Validation experiments confirmed the DDLS selectivity of deguelin, emetine, and SN-38 and showed that they induce apoptosis in DDLS cells. SN-38 had the lowest IC50 (approximately 10 nmol/L), and its pro-apoptotic effects were countered by knockdown of CEBPA but not of TP53. Irinotecan significantly inhibited tumor growth at well-tolerated doses, induced nuclear expression of C/EBPα, and inhibited HIF1α expression in DDLS patient-derived and cancer cell line xenograft models. In contrast, doxorubicin, the most common treatment for nonresectable DDLS, reduced tumor growth by 30% to 50% at a dose that caused weight loss. CONCLUSIONS This high-content screen revealed potential treatments for DDLS. These include irinotecan, which induces apoptosis of DDLS cells in a C/EBPα-dependent, p53-independent manner, and should be clinically evaluated in patients with advanced DDLS.
Collapse
Affiliation(s)
- Christina V Angeles
- Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Ana Velez
- Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Jordan Rios
- Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Bernadette Laxa
- Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - David Shum
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Penelope D Ruiz
- Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Yawei Shen
- Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Irina Ostrovnaya
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Rodrigo Gularte-Mérida
- Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Benjamin A Nacev
- Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Mark A Dickson
- Department of Medicine, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York
| | - Hakim Djaballah
- Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, New York
| | - Tomoyo Okada
- Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York.
| | - Samuel Singer
- Sarcoma Biology Laboratory, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York. .,Department of Surgery, Weill Cornell Medical College, New York, New York
| |
Collapse
|
5
|
Nascimento Mello AL, Sagrillo FS, de Souza AG, Costa ARP, Campos VR, Cunha AC, Imbroisi Filho R, da Costa Santos Boechat F, Sola-Penna M, de Souza MCBV, Zancan P. Selective AMPK activator leads to unfolded protein response downregulation and induces breast cancer cell death and autophagy. Life Sci 2021; 276:119470. [PMID: 33831423 DOI: 10.1016/j.lfs.2021.119470] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 03/18/2021] [Accepted: 03/25/2021] [Indexed: 12/25/2022]
Abstract
AIMS AMPK plays a critical role regulating cell metabolism, growth and survival. Interfering with this enzyme activity has been extensively studied as putative mechanism for cancer therapy. The present work aims to identify a specific AMPK activator for cancer cells among a series of novel heterocyclic compounds. MATERIALS AND METHODS A series of novel hybrid heterocyclic compounds, namely naphtoquinone-4-oxoquinoline and isoquinoline-5,8-quinone-4-oxoquinoline derivatives, were synthesized via Michael reaction and their structures confirmed by spectral data: infrared; 1H and 13C NMR spectroscopy (COSY, HSQC, HMBC); and high-resolution mass spectrometry (HRMS). The novel compounds were screened and tested for antitumoral activity and have part of their mechanism of action scrutinized. KEY FINDINGS Here, we identified a selective AMPK activator among the new hybrid heterocyclic compounds. This new compound presents selective cytotoxicity on breast cancer cells but not on non-cancer counterparts. We identified that by specifically activating AMPK in cancer cells, the drug downregulates unfolded protein response pathway, as well as inhibits mTOR signaling. SIGNIFICANCE These effects, that are selective for cancer cells, lead to activation of autophagy and, ultimately, to cancer cells death. Taken together, our data support the promising anticancer activity of this novel compound which is a strong modulator of metabolism.
Collapse
Affiliation(s)
- Angélica Lauria Nascimento Mello
- Laboratório de Oncobiologia Molecular (LabOMol), Departamento de Biotecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil
| | - Fernanda Savacini Sagrillo
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal Fluminense, 24010-141, Outeiro de São João Batista, s/n, Niterói, Rio de Janeiro, Brazil
| | - Alan Gonçalves de Souza
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal Fluminense, 24010-141, Outeiro de São João Batista, s/n, Niterói, Rio de Janeiro, Brazil
| | - Amanda Rodrigues Pinto Costa
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal Fluminense, 24010-141, Outeiro de São João Batista, s/n, Niterói, Rio de Janeiro, Brazil
| | - Vinícius Rangel Campos
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal Fluminense, 24010-141, Outeiro de São João Batista, s/n, Niterói, Rio de Janeiro, Brazil
| | - Anna Claudia Cunha
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal Fluminense, 24010-141, Outeiro de São João Batista, s/n, Niterói, Rio de Janeiro, Brazil
| | - Ricardo Imbroisi Filho
- Laboratório de Oncobiologia Molecular (LabOMol), Departamento de Biotecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil
| | - Fernanda da Costa Santos Boechat
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal Fluminense, 24010-141, Outeiro de São João Batista, s/n, Niterói, Rio de Janeiro, Brazil
| | - Mauro Sola-Penna
- Laboratório de Enzimologia e Controle do Metabolismo (LabECoM), Departamento de Biotecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil
| | - Maria Cecília Bastos Vieira de Souza
- Programa de Pós-Graduação em Química, Instituto de Química, Universidade Federal Fluminense, 24010-141, Outeiro de São João Batista, s/n, Niterói, Rio de Janeiro, Brazil.
| | - Patricia Zancan
- Laboratório de Oncobiologia Molecular (LabOMol), Departamento de Biotecnologia Farmacêutica, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ 21941-902, Brazil.
| |
Collapse
|
6
|
Sharma V, Das R, Mehta DK, Sharma D, Sahu RK. Exploring quinolone scaffold: Unravelling the chemistry of anticancer drug design. Mini Rev Med Chem 2021; 22:69-88. [PMID: 33438536 DOI: 10.2174/1389557521666210112142136] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2020] [Revised: 10/24/2020] [Accepted: 11/30/2020] [Indexed: 11/22/2022]
Abstract
Globally, cancer is considered as the major leading cause in decreasing the patient health care system of human beings. The growing threat from drug-resistant cancers makes heterocyclic moieties as an urgent need to develop more successful candidates for anti-cancer therapy. In view of outstanding pharmacological activities Quinolone and its derivatives have attracted more attention towards drug designing and biological evaluation in the search of new drug molecules. The inspired researchers attempted efforts in order to discover quinolone based analogs due to its wide range of biological activities. Due to immense pharmacological importance, distinct synthetic methods have been executed to attain new drug entities from quinolones and all the reported molecules have shown constructive anticancer activity. Some of the synthetic protocol like, one pot synthesis, post-Ugi-transformation, catalysed based synthesis, enzyme-based synthesis and nano-catalyst based synthetic procedures are also discussed as recent advancement in production of quinolone derivatives. In this review, recent synthetic approaches in the medicinal chemistry of quinolones and potent quinolone derivatives on the basis of structural activity relationship are outlined. Moreover, their major methods and modifications are discussed.
Collapse
Affiliation(s)
- Vishal Sharma
- MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Hr. India
| | - Rina Das
- MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Hr. India
| | - Dinesh Kumar Mehta
- MM College of Pharmacy, Maharishi Markandeshwar (Deemed to be University), Mullana, Ambala, Hr. India
| | - Diksha Sharma
- Faculty of Pharmaceutical Sciences, Kurukshetra University, Kurukshetra-Hr. India
| | - Ram Kumar Sahu
- Dept of Pharmaceutical Science, Assam University (A Central University), Silchar, Assam-788011. India
| |
Collapse
|
7
|
Ahadi H, Emami S. Modification of 7-piperazinylquinolone antibacterials to promising anticancer lead compounds: Synthesis and in vitro studies. Eur J Med Chem 2020; 187:111970. [DOI: 10.1016/j.ejmech.2019.111970] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/20/2019] [Revised: 11/23/2019] [Accepted: 12/11/2019] [Indexed: 02/03/2023]
|
8
|
Zhao Y, Wang J, Liu Y, Jiang Z, Song Y, Guo X. Enantioseparation using carboxymethyl-6-(4-methoxybenzylamino)-β-cyclodextrin as a chiral selector by capillary electrophoresis and molecular modeling study of the recognition mechanism. NEW J CHEM 2020. [DOI: 10.1039/c9nj04771a] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
In this study, carboxymethyl-6-(4-methoxybenzylamino)-β-cyclodextrin (CMCDPN) was synthesized for the first time and managed to be used as a chiral selector to enantioseparate 13 kinds of chiral drugs by capillary electrophoresis.
Collapse
Affiliation(s)
- Yu Zhao
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang
- P. R. China
| | - Jinlong Wang
- School of Life Science and Bio-Pharmaceutics
- Shenyang Pharmaceutical University
- Shenyang
- P. R. China
| | - Yanru Liu
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang
- P. R. China
| | - Zhen Jiang
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang
- P. R. China
| | - Yongbo Song
- School of Life Science and Bio-Pharmaceutics
- Shenyang Pharmaceutical University
- Shenyang
- P. R. China
| | - Xingjie Guo
- School of Pharmacy
- Shenyang Pharmaceutical University
- Shenyang
- P. R. China
| |
Collapse
|
9
|
Recent advances in the synthetic and medicinal perspective of quinolones: A review. Bioorg Chem 2019; 92:103291. [PMID: 31561107 DOI: 10.1016/j.bioorg.2019.103291] [Citation(s) in RCA: 72] [Impact Index Per Article: 14.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2019] [Revised: 09/12/2019] [Accepted: 09/16/2019] [Indexed: 12/16/2022]
Abstract
In the modern scenario, the quinolone scaffold has emerged as a very potent motif considering its clinical significance. Quinolones possess wide range of pharmacological activities such as anticancer, antibacterial, antifungal, antiprotozoal, antiviral, anti-inflammatory, carbonic anhydrase inhibitory and diuretic activity etc. The versatile synthetic approaches have been successfully applied and several of the resulted synthesized compounds exhibit fascinating biological activities in numerous fields. This has prompted to discover quinolone-based analogues among the researchers due to its great diversity in biological activities. In the past few years, various new, efficient and convenient synthetic approaches (including green chemistry and microwave-assisted synthesis) have been designed and developed to synthesize diverse quinolone-based scaffolds which represent a growing area of interest in academic and industry as well as to explore their biological activities. In this review, an attempt has been made by the authors to summarize (1) One of the most comprehensive listings of quinolone-based drugs or agents in the market or under various stages of clinical development; (2) Recent advances in the synthetic strategies for quinolone derivatives as well as their biological implications including insight of mechanistic studies. (3) Further, the biological data is correlated with structure-activity relationship studies to provide an insight into the rational design of more active agents.
Collapse
|
10
|
Abdel‐Aal MAA, Abdel‐Aziz SA, Shaykoon MSA, Abuo‐Rahma GEA. Towards anticancer fluoroquinolones: A review article. Arch Pharm (Weinheim) 2019; 352:e1800376. [DOI: 10.1002/ardp.201800376] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Revised: 03/18/2019] [Accepted: 03/21/2019] [Indexed: 12/21/2022]
Affiliation(s)
- Mohamed A. A. Abdel‐Aal
- Department of Medicinal Chemistry, Faculty of PharmacyMinia UniversityMinia Egypt
- Department of Pharmaceutical Chemistry, Faculty of PharmacyAl‐Azhar UniversityAssiut Egypt
| | - Salah A. Abdel‐Aziz
- Department of Pharmaceutical Chemistry, Faculty of PharmacyAl‐Azhar UniversityAssiut Egypt
| | | | | |
Collapse
|
11
|
Gao F, Zhang X, Wang T, Xiao J. Quinolone hybrids and their anti-cancer activities: An overview. Eur J Med Chem 2019; 165:59-79. [DOI: 10.1016/j.ejmech.2019.01.017] [Citation(s) in RCA: 105] [Impact Index Per Article: 21.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2018] [Revised: 01/07/2019] [Accepted: 01/08/2019] [Indexed: 01/23/2023]
|
12
|
Maračić S, Lapić J, Djaković S, Opačak-Bernardi T, Glavaš-Obrovac L, Vrček V, Raić-Malić S. Quinoline and ferrocene conjugates: Synthesis, computational study and biological evaluations. Appl Organomet Chem 2018. [DOI: 10.1002/aoc.4628] [Citation(s) in RCA: 12] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
Affiliation(s)
- Silvija Maračić
- Department of Organic Chemistry, Faculty of Chemical Engineering and Technology; University of Zagreb; Marulićev trg 19 10000 Zagreb Croatia
| | - Jasmina Lapić
- Laboratory for Organic Chemistry, Faculty of Food Technology and Biotechnology; University of Zagreb; Pierottijeva 6 10000 Zagreb Croatia
| | - Senka Djaković
- Laboratory for Organic Chemistry, Faculty of Food Technology and Biotechnology; University of Zagreb; Pierottijeva 6 10000 Zagreb Croatia
| | - Teuta Opačak-Bernardi
- Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine; Josip Juraj Strossmayer University of Osijek; J. Huttlera 4 31000 Osijek Croatia
| | - Ljubica Glavaš-Obrovac
- Department of Medical Chemistry, Biochemistry and Clinical Chemistry, Faculty of Medicine; Josip Juraj Strossmayer University of Osijek; J. Huttlera 4 31000 Osijek Croatia
| | - Valerije Vrček
- Faculty of Pharmacy and Biochemistry; University of Zagreb; A. Kovačića 1 10000 Zagreb Croatia
| | - Silvana Raić-Malić
- Department of Organic Chemistry, Faculty of Chemical Engineering and Technology; University of Zagreb; Marulićev trg 19 10000 Zagreb Croatia
| |
Collapse
|
13
|
Zhang ZH, Wu HM, Deng SN, Chai RX, Mwenda MC, Peng YY, Cai D, Chen Y. Synthesis and biological evaluation of 2,4-disubstituted thiazole amide derivatives as anticancer agent. CHEMICAL PAPERS 2018. [DOI: 10.1007/s11696-018-0587-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|